Baby Safety / Compounds / Sildenafil (PDE5 inhibitors)

Is Sildenafil (PDE5 inhibitors) safe for babies and kids?

Moderate risk for kids

Infants have immature drug-metabolizing enzymes (CYP450 ontogeny), reduced renal clearance, and different volume of distribution. Accidental exposure or breast milk transfer of Sildenafil (PDE5 inhibitors) poses heightened risk.

What is sildenafil (pde5 inhibitors)?

The IUPAC name is 5-[2-ethoxy-5-(4-methylpiperazin-1-yl)sulfonylphenyl]-1-methyl-3-propyl-6H-pyrazolo[4,5-d]pyrimidin-7-one.

Also known as: 5-[2-ethoxy-5-(4-methylpiperazin-1-yl)sulfonylphenyl]-1-methyl-3-propyl-6H-pyrazolo[4,5-d]pyrimidin-7-one, sildenafil, Aphrodil, Vizarsin.

IUPAC name
5-[2-ethoxy-5-(4-methylpiperazin-1-yl)sulfonylphenyl]-1-methyl-3-propyl-6H-pyrazolo[4,5-d]pyrimidin-7-one
CAS number
139755-83-2
Molecular formula
C22H30N6O4S
Molecular weight
474.6 g/mol
SMILES
CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C
PubChem CID
135398744

Risk for babies

Moderate risk

Infants have immature drug-metabolizing enzymes (CYP450 ontogeny), reduced renal clearance, and different volume of distribution. Accidental exposure or breast milk transfer of Sildenafil (PDE5 inhibitors) poses heightened risk.

Neonates and infants up to 12 months have incomplete blood-brain barrier development, immature Phase I/II metabolic enzymes (particularly CYP3A4, UGT1A1), and higher gastrointestinal permeability. Equivalent doses produce higher internal concentrations and longer residence times.

What to do: Minimize infant exposure through source control. For breastfeeding mothers: reduce maternal exposure. For formula-fed infants: use certified low-migration bottles and verified water sources. Consult pediatrician regarding any concerns.

Risk for pregnant and nursing people

Elevated risk

Sildenafil (PDE5 inhibitors) poses pregnancy risk through potential teratogenicity, altered pharmacokinetics (increased blood volume, changed CYP activity), and placental transfer. FDA pregnancy category should be evaluated.

Suspected reproductive toxicant (GHS H361) or suspected endocrine disruptor. Precautionary approach warranted. Animal studies or limited human data suggest developmental toxicity potential.

What to do: Minimize exposure during pregnancy and lactation. Consult healthcare provider regarding specific risks. Consider alternative products with lower hazard profiles.

Regulatory consensus

3 regulatory and scientific bodies have classified Sildenafil (PDE5 inhibitors). The classifications differ — that's the data.

AgencyYearClassificationNotes
FDA—Approved for erectile dysfunction (ED) in menAt standard doses 25–100 mg as needed
FDA—Approved for pulmonary arterial hypertension (PAH)Revatio formulation, all sexes, at lower doses 20 mg TID
US—Prescription-onlyCurrent status; OTC proposals have been reviewed but not approved

Regulators apply different standards of evidence — animal-data weighting, exposure-pattern assumptions, epidemiological power thresholds — which is why two scientific bodies can review the same data and reach different conclusions. The disagreement is the data.

Where kids encounter sildenafil (pde5 inhibitors)

  • Industrial Facilities — Manufacturing plants, Chemical storage areas, Waste treatment sites
  • Occupational Environments — Factories, Warehouses, Transportation vehicles

Safer alternatives

Lower-risk approaches that achieve a similar outcome to Sildenafil (PDE5 inhibitors):

  • Alternative drug class; Non-pharmacological therapy; Lowest effective dose
    Trade-offs: Direct chemical substitution requires verification that the replacement does not introduce new hazards (regrettable substitution). Conduct full hazard assessment of proposed alternative before adoption.
    Relative cost: 1.2-2×

Frequently asked questions

Is sildenafil (pde5 inhibitors) safe for kids?

Infants have immature drug-metabolizing enzymes (CYP450 ontogeny), reduced renal clearance, and different volume of distribution. Accidental exposure or breast milk transfer of Sildenafil (PDE5 inhibitors) poses heightened risk.

What products contain sildenafil (pde5 inhibitors)?

Sildenafil (PDE5 inhibitors) appears in: Manufacturing plants (Industrial facilities); Chemical storage areas (Industrial facilities); Factories (Occupational environments); Warehouses (Occupational environments).

What should I do if my child is exposed to sildenafil (pde5 inhibitors)?

Minimize infant exposure through source control. For breastfeeding mothers: reduce maternal exposure. For formula-fed infants: use certified low-migration bottles and verified water sources. Consult pediatrician regarding any concerns.

Why do regulators disagree about sildenafil (pde5 inhibitors)?

Sildenafil (PDE5 inhibitors) has been classified by 3 agencies including FDA, FDA, US, with differing conclusions. Regulators apply different standards of evidence (animal data weighting, exposure-pattern assumptions, epidemiological power thresholds), which is why two scientific bodies can review the same data and reach different conclusions. See the regulatory consensus table on this page for the full picture.

See Sildenafil (PDE5 inhibitors) in the baby app

Look up products containing sildenafil (pde5 inhibitors), compare to alternatives, and explore the full data record.

Open in baby View raw API data

Sources (3)
  1. US FDA: Sildenafil (Viagra/Revatio) Prescribing Information — Erectile Dysfunction, Pulmonary Arterial Hypertension, Nitrate Contraindication, and Cardiovascular Risk (2020) — regulatory
  2. ASPCA Animal Poison Control Center: Sildenafil and PDE5 Inhibitor Toxicosis in Dogs — Hypotension, Clinical Signs, and Supportive Management (2023) — veterinary
  3. Plumb's Veterinary Drug Handbook (10th ed.) — Sildenafil: Veterinary Use for Pulmonary Hypertension and Accidental Ingestion Management (2023) — veterinary

Reference data, not professional advice. Aggregates publicly available regulatory and scientific data; not a substitute for veterinary, medical, legal, or regulatory advice. Why we built ALETHEIA →